Reverse Cardiac Remodeling and Outcome After Initiation of Sacubitril/Valsartan

Januzzi, James L.; Camacho, Alexander; Piña, Ileana L.; Rocha, Ricardo; Williamson, Kristin M.; Maisel, Alan S.; Felker, G. Michael; Prescott, Margaret F.; Butler, Javed; Solomon, Scott D.

doi:10.1161/circheartfailure.119.006946

Cited by 35 publications

(30 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…9 Briefly, this was a 52-week, multicentre, open-label, single-arm study that enrolled 794 patients with chronic HFrEF who were then initiated and titrated on S/V per United States prescribing information. 8,9 Whenever possible, the dose of S/V was titrated to the target dose of 97/103 mg twice…”

Section: Prove-hf Study Design and Participantsmentioning

confidence: 99%

“…Cardiac reverse remodelling was defined by changes in LVEF, LV end-diastolic volume index (LVEDVi; normal <76 mL/m 2 ), and LV end-systolic volume index (LVESVi; normal <30 mL/m 2 ) after S/V initiation. 8 Blood samples were collected from participants at each study visit and sent to a central laboratory for measurement of plasma NT-proBNP using a commercially available electrochemiluminescence immunoassay (proBNP II, Roche Diagnostics).…”

Section: Prove-hf Study Design and Participantsmentioning

confidence: 99%

“…9 All adverse events and serious adverse events were recorded; suspected cases of angioedema were evaluated by a central adjudication panel. 8…”

Section: Prove-hf Study Design and Participantsmentioning

confidence: 99%

“…Sacubitril/valsartan (S/V), a combined angiotensin receptor-neprilysin inhibitor (ARNI), is among the newest guideline-supported options for treatment of HFrEF 6 reducing risk in patients affected by chronic HFrEF. 7 Most recently, the Prospective Study of Biomarkers, Symptom Improvement and Ventricular Remodeling During Entresto Therapy for Heart Failure (PROVE-HF; NCT02887183) study 8 suggested that S/V had favourable effects on measures of cardiac remodelling in patients with chronic HFrEF. Longitudinal changes in measures of cardiac reverse remodelling were also strongly associated with simultaneous reductions in N-terminal pro B-type natriuretic peptide (NT-proBNP) concentrations.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Sex‐based differences in biomarkers, health status, and reverse cardiac remodelling in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan

Ibrahim

Piña

Camacho

et al. 2020

European J of Heart Fail

Self Cite

View full text Add to dashboard Cite

Aims We sought to determine sex‐based differences in biomarkers, self‐reported health status, and magnitude of longitudinal changes in measures of reverse cardiac remodelling among patients with heart failure with reduced ejection fraction (HFrEF, left ventricular ejection fraction ≤40%) treated with sacubitril/valsartan (S/V). Methods and results This was a subgroup analysis of patients initiated on S/V in the Prospective Study of Biomarkers, Symptom Improvement and Ventricular Remodeling During Entresto Therapy for Heart Failure (PROVE‐HF) study. There were 226 (28.5%) women in the study. Though women had lower baseline N‐terminal pro B‐type natriuretic peptide (NT‐proBNP), they had more rapid early reduction in the biomarker after initiation of S/V. Compared to men, women had lower average baseline Kansas City Cardiomyopathy Questionnaire (KCCQ)‐23 Total Symptom score (67.6 vs. 71.9; P = 0.003) but showed greater linear improvement (7.4 vs. 5.5 points; P < 0.001) and faster pace of KCCQ change (P < 0.001) over the course of the trial. Women and men demonstrated similar degrees of reverse left ventricular remodelling following S/V initiation; however, women did so earlier than men with more consistent changes. These results remained unchanged with adjustment for relevant covariates. Reduction in NT‐proBNP was associated with reverse cardiac remodelling in both women and men. Treatment with S/V was well tolerated in all. Conclusions In women with HFrEF, treatment with S/V was associated with significant NT‐proBNP reduction, health status improvement and reverse cardiac remodelling.

show abstract

Section: Prove-hf Study Design and Participantsmentioning

confidence: 99%

Section: Prove-hf Study Design and Participantsmentioning

confidence: 99%

“…9 All adverse events and serious adverse events were recorded; suspected cases of angioedema were evaluated by a central adjudication panel. 8…”

Section: Prove-hf Study Design and Participantsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Sex‐based differences in biomarkers, health status, and reverse cardiac remodelling in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan

Ibrahim

Piña

Camacho

et al. 2020

European J of Heart Fail

Self Cite

View full text Add to dashboard Cite

show abstract

“…Several studies have tried to identify the useful or detrimental effect of exosomal miRNAs on pathological cardiac remodeling after MI. The recently approved heart failure drug sacubitril/valsartan, a neprilysin inhibitor and angiotensin receptor blocker, improves cardiac function and reverses myocardial remodeling [ 87 ]. Modulation of miRNA content in plasma exosomes could explain its cardiac effects.…”

Section: Introductionmentioning

confidence: 99%

A Brief Review on the Biology and Effects of Cellular and Circulating microRNAs on Cardiac Remodeling after Infarction

Parikh

Pierce

2021

IJMS

View full text Add to dashboard Cite

Despite advances in diagnostic, prognostic, and treatment modalities, myocardial infarction (MI) remains a leading cause of morbidity and mortality. Impaired cellular signaling after an MI causes maladaptive changes resulting in cardiac remodeling. MicroRNAs (miRNAs/miR) along with other molecular components have been investigated for their involvement in cellular signaling in the pathogenesis of various cardiac conditions like MI. miRNAs are small non-coding RNAs that negatively regulate gene expression. They bind to complementary mRNAs and regulate the rate of protein synthesis by altering the stability of their targeted mRNAs. A single miRNA can modulate several cellular signaling pathways by targeting hundreds of mRNAs. This review focuses on the biogenesis and beneficial effects of cellular and circulating (exosomal) miRNAs on cardiac remodeling after an MI. Particularly, miR-1, -133, 135, and -29 that play an essential role in cardiac remodeling after an MI are described in detail. The limitations that will need to be addressed in the future for the further development of miRNA-based therapeutics for cardiovascular conditions will also be discussed.

show abstract

Angiotensin Receptor–Neprilysin Inhibition (ARNI) Therapy and Reverse Remodeling in Heart Failure With Reduced Ejection Fraction

Drazner

2019

JAMA

View full text Add to dashboard Cite

show abstract

Reverse Cardiac Remodeling and Outcome After Initiation of Sacubitril/Valsartan

Cited by 35 publications

References 4 publications

Sex‐based differences in biomarkers, health status, and reverse cardiac remodelling in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan

Sex‐based differences in biomarkers, health status, and reverse cardiac remodelling in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan

A Brief Review on the Biology and Effects of Cellular and Circulating microRNAs on Cardiac Remodeling after Infarction

Angiotensin Receptor–Neprilysin Inhibition (ARNI) Therapy and Reverse Remodeling in Heart Failure With Reduced Ejection Fraction

Contact Info

Product

Resources

About